.jpg "Radnet (NASDAQ: RDNT)")
Today, the Medical Director of Radnet (NASDAQ: RDNT), John Crues, sold shares of RDNT for $195.1K.
Following John Crues’ last RDNT Sell transaction on December 20, 2017, the stock climbed by 3.1%.
See today’s analyst top recommended stocks >>
Based on Radnet’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $231 million and GAAP net loss of $7.34 million. In comparison, last year the company earned revenue of $229 million and had a GAAP net loss of $1.21 million. Currently, Radnet has an average volume of 53.13K. The Company has a Price to Book ratio of 7.9340.
The insider sentiment on Radnet has been negative according to 55 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
John Crues’ trades have generated a -15.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures.
